secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lantheus Holdings, Inc. (LNTH)
CIK:        0001521036
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001193125-22-283698
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lantheus enters two license/collaboration deals with POINT for up to $1.87B in milestones, $260M upfront
--------------------------------------------------------------------------------

- Upfront cash: $250M for PNT-2002 (PSMA therapy) and $10M for PNT-2003 (SSTR therapy); combined potential milestones ~$1.87B.
- PNT-2002 targets PSMA for metastatic castrate-resistant prostate cancer; POINT responsible for clinical development.
- PNT-2003 targets SSTR-positive neuroendocrine tumors; Lantheus leads regulatory filings and commercialization post-approval.
- Royalties: 20% PNT-2002 net sales after $500M cumulative gross profit; 15% PNT-2003 net sales.
- Closing subject to HSR review; outside date June 30, 2023 (extendable by Lantheus to Aug 30, 2023).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1521036/000119312522283698/0001193125-22-283698-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1521036/000119312522283698/d378760d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-283698

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer